Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethoxycarbonyl Group SCHEMBL28768212 | 0.82 | NR4A2 (0.45) | DYRK1AHTR2ANR4A2SLC6A4REN | |
| SCHEMBL28251367 | 0.80 | DYRK1A (0.60) | DYRK1AHTR2ANR4A2SLC6A4AR | |
| SCHEMBL2143637 | 0.80 | TRIM24 (0.60) | HTR2ANR4A2ATMARREN | |
| SCHEMBL31607554 | 0.80 | TRIM24 (0.60) | HTR2ANR4A2ATMARREN | |
| SCHEMBL15692504 | 0.78 | REN (0.57) | HTR2ANR4A2ATMARREN | |
| SCHEMBL16727192 | 0.77 | DYRK1A (0.53) | DYRK1AHTR2ANR4A2ATMAR | |
| SCHEMBL5248011 | 0.77 | ATM (0.48) | HTR2ANR4A2ATMRENCYP1A2 | |
| SCHEMBL1137500 | 0.75 | DYRK1A (0.55) | DYRK1AHTR2ANR4A2SLC6A4ATM | |
| SCHEMBL7089054 | 0.75 | REN (0.50) | HTR2ANR4A2ATMRENTRIM24 | |
| SCHEMBL3221554 | 0.75 | GPR84 (0.58) | HTR2ASLC6A4ATMARREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183394-A1 | ALPHA 1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023018747-A1 | INHIBITORS OF HYPOXIA-INDUCIBLE FACTORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20180037917-A1 | PROTECTING GROUP CHEMISTRY FOR CLEAN, REDUCTANT-FREE DYEING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-08 | — | — | US | disclosed |
| EP-1465880-B1 | 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE TO TREAT DISORDERS ASSOCIATED WITH SOMATOSTATINE | IPSEN PHARMA (FR) | 2009-08-05 | — | — | EP | disclosed |
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-7517899-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090093469-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-09 | — | — | US | disclosed |
| EP-1732887-B1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| CN-1960973-A | 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine(NE) and the serotonine(5-HT) activity and the monoamine reuptake | WYETH CORP (US) | 2007-05-09 | — | — | CN | disclosed |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | DYRK1A 1728/4885HTR2A 58/4885NR4A2 4086/4885 |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | PAH, PNMT, COMT | DYRK1A 1728/4885HTR2A 58/4885NR4A2 4086/4885 |
| US-20090093469-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | DYRK1A 1728/4885HTR2A 58/4885NR4A2 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.